Just rooting around in the short selling data. In answer to your volume question 7th July was the day on which the Lecanamab FDA approval news was released to market, the net number of CGS shares sold short on that day was 802,046 ... leading to a total closing short position of 1,403,440 shares on the close of 07/07/23.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
-0.090(4.99%) |
Mkt cap ! $291.1M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.81 | $1.69 | $138.9K | 78.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 600 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |